Advances in Early-Stage Urothelial Cancer: Expert Guidance for a New Treatment Algorithm

Join us for this virtual satellite symposium at AUA 2021 on early-stage urothelial carcinoma! Hear expert perspectives on incorporating neoadjuvant and adjuvant therapy into the management of NMIBC and the latest data on optimal management of upper tract urothelial cancer. Attendees will have the opportunity to address questions to the faculty panel.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the event.


  • Welcome and Introductions
  • Current Approaches to NMIBC
  • New Approaches to Low-Grade UTUC
  • Neoadjuvant/Adjuvant Therapy for High-Grade Invasive UTUC
  • Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Seth P. Lerner, MD

Professor of Urology
Beth and Dave Swalm Chair in Urologic Oncology
Vice Chair,
Faculty Affairs
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Jean Hoffman-Censits, MD

Associate Professor
Department of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Surena Matin, MD

Division of Surgery
Department of Urology
MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with early-stage UC.

Target Audience
This program is intended for urologists and other healthcare professionals who care for patients with UC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with UTUC most likely to benefit from primary chemoablation therapy relative to ureteronephrectomy
  • Select appropriate treatment for patients with NMIBC that is unresponsive to BCG
  • Describe the proper technique for instillation of chemoablation therapy with reverse thermal gel in patients with early-stage UC
  • Critically appraise the risks and benefits of available and emerging intravesical therapies and immunotherapies relative to early cystectomy in patients with NMIBC
  • Refer patients with early-stage UC for enrollment in clinical trials investigating novel therapies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.